Marion Fiorentino1,2, Luis Sagaon-Teyssier1,2, Khadim Ndiaye1,2, Marie Suzan-Monti1,2, Marie-Thérèse Mengue3, Laurent Vidal1,2, Christopher Kuaban4, Laura March5, Christian Laurent5, Bruno Spire1,2, Sylvie Boyer1,2. 1. 1 INSERM, IRD, Aix Marseille Université, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, Marseille, France. 2. 2 ORS PACA (Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur), Marseille, France. 3. 3 Université Catholique d'Afrique Centrale, Yaoundé, Cameroun. 4. 4 Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon. 5. 5 IRD UMI 233-INSERM U1175, Montpellier University, Montpellier, France.
Abstract
BACKGROUND: Intimate partner violence in its various forms increases HIV exposure in female victims and potentially jeopardizes the HIV treatment cascade, for instance, by impeding engagement in and adherence to care. Elevated rates of HIV and intimate partner violence are reported in Central Africa. Evidence on the effect of intimate partner violence on antiviral therapy interruption is lacking in Cameroon, where only 330,000 women live with HIV and only 19% of HIV-positive people are virally suppressed. This study aimed to assess the prevalence and factors of intimate partner violence against HIV-positive women and its relationship with antiretroviral therapy interruption ⩾1 month. METHODS: The EVOLCam cross-sectional survey was conducted in 19 hospitals in the Center and Littoral regions. The study sample comprised antiviral therapy-treated women declaring at least one sexual partner in the previous year. Scores of recent emotional, physical, extreme physical and sexual intimate partner violence were built using principal component analysis and categorized under no, occasional or frequent intimate partner violence. Multivariate logistic analyses were performed to investigate the relationship between intimate partner violence and recent antiretroviral therapy interruption ⩾1 month, and associated factors. RESULTS: Among the 894 analyzed women, the prevalence of intimate partner violence was 29% (emotional), 22% (physical), 13% (extreme physical) and 18% (sexual). Frequent physical intimate partner violence was a significant risk factor of antiretroviral therapy interruption ⩾1 month (adjusted odds ratio = 2.42 (95% confidence interval = 1.00; 5.87)). It was also associated with HIV-related stigma (2.53 (1.58; 4.02)), living with a main partner (2.03 (1.20; 3.44) and non-defensive violence against this partner (5.75 (3.53; 9.36)). CONCLUSION: Intimate partner violence is a potential barrier to antiviral therapy continuity and aggravates vulnerability of Cameroonian HIV-positive women. The prevention and detection of intimate partner violence by HIV services might help to reach the last "90" of the 90-90-90 targets.
BACKGROUND: Intimate partner violence in its various forms increases HIV exposure in female victims and potentially jeopardizes the HIV treatment cascade, for instance, by impeding engagement in and adherence to care. Elevated rates of HIV and intimate partner violence are reported in Central Africa. Evidence on the effect of intimate partner violence on antiviral therapy interruption is lacking in Cameroon, where only 330,000 women live with HIV and only 19% of HIV-positive people are virally suppressed. This study aimed to assess the prevalence and factors of intimate partner violence against HIV-positive women and its relationship with antiretroviral therapy interruption ⩾1 month. METHODS: The EVOLCam cross-sectional survey was conducted in 19 hospitals in the Center and Littoral regions. The study sample comprised antiviral therapy-treated women declaring at least one sexual partner in the previous year. Scores of recent emotional, physical, extreme physical and sexual intimate partner violence were built using principal component analysis and categorized under no, occasional or frequent intimate partner violence. Multivariate logistic analyses were performed to investigate the relationship between intimate partner violence and recent antiretroviral therapy interruption ⩾1 month, and associated factors. RESULTS: Among the 894 analyzed women, the prevalence of intimate partner violence was 29% (emotional), 22% (physical), 13% (extreme physical) and 18% (sexual). Frequent physical intimate partner violence was a significant risk factor of antiretroviral therapy interruption ⩾1 month (adjusted odds ratio = 2.42 (95% confidence interval = 1.00; 5.87)). It was also associated with HIV-related stigma (2.53 (1.58; 4.02)), living with a main partner (2.03 (1.20; 3.44) and non-defensive violence against this partner (5.75 (3.53; 9.36)). CONCLUSION: Intimate partner violence is a potential barrier to antiviral therapy continuity and aggravates vulnerability of Cameroonian HIV-positive women. The prevention and detection of intimate partner violence by HIV services might help to reach the last "90" of the 90-90-90 targets.
Entities:
Keywords:
Cameroon; HIV; antiretroviral therapy interruption; intimate partner violence; women
Authors: Lilia Blima Schraiber; Maria do Rosário Dias O Latorre; Ivan França; Neuber José Segri; Ana Flávia Pires Lucas D'Oliveira Journal: Rev Saude Publica Date: 2010-08 Impact factor: 2.106
Authors: Tanya Abramsky; Charlotte H Watts; Claudia Garcia-Moreno; Karen Devries; Ligia Kiss; Mary Ellsberg; Henrica Afm Jansen; Lori Heise Journal: BMC Public Health Date: 2011-02-16 Impact factor: 3.295
Authors: Lawrence Mbuagbaw; Lehana Thabane; Pierre Ongolo-Zogo; David Yondo; Stephen Noorduyn; Marek Smieja; Lisa Dolovich Journal: AIDS Res Ther Date: 2012-12-19 Impact factor: 2.250
Authors: Angela M Parcesepe; Evette Cordoba; John A Gallis; Jennifer Headley; Berenger Tchatchou; John Hembling; Claudian Soffo; Joy Noel Baumgartner Journal: BMC Pregnancy Childbirth Date: 2021-03-04 Impact factor: 3.007
Authors: Muluken Dessalegn Muluneh; Virginia Stulz; Lyn Francis; Kingsley Agho Journal: Int J Environ Res Public Health Date: 2020-02-01 Impact factor: 3.390
Authors: Na Wang; Bo Huang; Yuhua Ruan; K Rivet Amico; Sten H Vermund; Shimin Zheng; Han-Zhu Qian Journal: BMC Public Health Date: 2020-02-10 Impact factor: 3.295
Authors: Marion Fiorentino; Abdourahmane Sow; Luis Sagaon-Teyssier; Marion Mora; Marie-Thérèse Mengue; Laurent Vidal; Christopher Kuaban; Laura March; Christian Laurent; Bruno Spire; Sylvie Boyer Journal: PLoS One Date: 2021-02-18 Impact factor: 3.240
Authors: Elizabeth C Wetzel; Tapiwa Tembo; Elaine J Abrams; Alick Mazenga; Mike J Chitani; Saeed Ahmed; Xiaoying Yu; Maria H Kim Journal: Malawi Med J Date: 2021-12 Impact factor: 0.875
Authors: Melissa Meinhart; Ilana Seff; Katrina Troy; Samantha McNelly; Luissa Vahedi; Catherine Poulton; Lindsay Stark Journal: Int J Environ Res Public Health Date: 2021-06-29 Impact factor: 3.390